Tovecimig

Tovecimig (CTX-009) is a bispecific antibody developed by Compass Therapeutics. Its target is VEGF / VEGFR (the sponsor names DLL4 x VEGF-A). The sponsor states: Simultaneously targets Delta-like ligand 4 (DLL4) and VEGF-A to inhibit tumour angiogenesis. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05506943 (A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)), in biliary tract cancer and bladder & urothelial cancer. The largest, NCT05506943, plans to enrol 168 participants (actual) with primary completion expected 2027-08-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.